Comparing Cost-Effectiveness Analyses for the Clinical Oncology Setting: The Example of the Gynecologic Oncology Group 111 Trial

References

• Smith T J, Hillner B E, Desch C E. Efficacy and cost effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993; 85: 1460–1474
   PubMed Web of Science ®Google Scholar
• Berenson R, Holahan J. Sources of the growth in medicare physician expenditures. JAMA 1992; 267: 687–91
   PubMed Web of Science ®Google Scholar
• Schwartz W B, Mendelson D M. Hospital cost containment in the 1980s. Hard lessons learned and prospects for the 1990s. N Engl JMed 1991; 324: 1037–1042
   PubMed Web of Science ®Google Scholar
• Cleri L B, Kris M G, Tyson L B, et al. Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin. Cancer 1995; 76: 774–778
   PubMed Web of Science ®Google Scholar
• Doyle C, Stockier M, Pintilie M, et al. Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol 1997; 15: 1000–1007
   PubMed Web of Science ®Google Scholar
• Doyle J J, Dezii C, Sadana M. A. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer. Semin Oncol 1996; 23(6 Suppl 13)51–60
   PubMed Web of Science ®Google Scholar
• Meisenberg B R, Miller W E, McMillan R, et al. Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 1997; 15: 11–17
   PubMed Web of Science ®Google Scholar
• Bennett C L, Armitage J L, Armitage G O, et al. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska, 1987–91. J Clin Oncol 1995; 13: 969–73
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Sutcliffe S B. Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma. Leuk Lymph 1995; 17: 139–145
   PubMed Web of Science ®Google Scholar
• Bennett C L, Golub R M, Waters T M, et al. Economic analyses of phase III cooperative cancer group trials: are they feasible. Cancer Invest 1997; 15: 227–236
   PubMed Web of Science ®Google Scholar
• Troxel S A, Winfield H N. Comparative financial analysis of laparoscopic pelvic lymph node dissection performed in 1990–92 v. 1993–94. J Endourol 1996; 10: 353–359
   PubMed Web of Science ®Google Scholar
• Abu-Rustum N R, Barakat R R, Siegel P L, et al. Second-look operation for epithelial ovarian cancer: laparoscopy or laparotomy?. Obstet Gynecol 1996; 88: 549–553
   PubMed Web of Science ®Google Scholar
• Fleshman J W, Nelson H, Peters W R, et al. Early results of laparoscopic surgery for colorectal cancer. Retrospective analysis of 372 patients treated by Clinical Outcomes of Surgical Therapy Study Group. Dis Colon Rect 1996; 39(10 Suppl)S53–S58
   PubMed Web of Science ®Google Scholar
• Russell L B, Gold M R, Siegel J E, et al. The role of cost effectiveness analysis in health and medicine. JAMA 1996; 276: 1172–1177
   PubMed Web of Science ®Google Scholar
• Weinstein M C, Siegel J E, Gold M R, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1253–1258
   PubMed Web of Science ®Google Scholar
• Siegel J E, Weinstein M C, Russell L B, et al. Recommendations for reporting cost-effectiveness analyses. JAMA 1996; 276: 1339–1341
   PubMed Web of Science ®Google Scholar
• Earle C C, Coyle D, Evans W K. Cost-effectiveness analysis in oncology. Ann Oncol 1998; 9: 475–482
   PubMed Web of Science ®Google Scholar
• McGuire W, Neugut A I, Arikian S, et al. Analysis of the costeffectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997; 15: 640–645
   PubMed Web of Science ®Google Scholar
• Elit L M, Garni A, Levine M N. Economic and policy implications of adopting paclitaxel asfirst-line therapy for advanced ovarian cancer: an Ontario perspective. J Clin Oncol 1997; 15: 632–639
   PubMed Web of Science ®Google Scholar
• McGuire W P, Hoskins W J, Brady M F, et al. Cyclophosphamide and cisplatin compared to paclitaxel and cisplatin in patients with stage 3 and 4 ovarian cancer. N Engl J Med 1996; 334: 1–6
   PubMed Web of Science ®Google Scholar
• Bennett C L, Golub R M, Calhoun E A, et al. Cost-utility assessment of amifostine as first-line therapy for ovarian cancer. Int J Gynecol Cancer 1998; 8: 64–72
   Web of Science ®Google Scholar
• Hayman J A, Fairclough D L, Harris J R, et al. Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer. J Clin Oncol 1997; 15: 1252–1260
   PubMed Web of Science ®Google Scholar
• Bennett C L, Chapman G, Elstein A S, et al. A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians. Eur Urol 1997; 32: 86–88
   PubMed Web of Science ®Google Scholar
• DeCoster C A, Brownell M D. Private health care in Canada: savior or siren?. Public Health Rep 1997; 112: 299–305
   Google Scholar
• Bennett C L, Westerman I L. Economic analysis during phase III clinical trials: who, what, when, where and why?. Oncology 1995; 9: 1–7
   Google Scholar
• Rundle R L. Salick pioneers selling cancer care to HMOs. The Wall Street Journal Monday, August, 1996; 12: B1–B2
   Google Scholar
• Garner T I, Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care 1987; 25: 25–34
   PubMed Web of Science ®Google Scholar
• Waters T M. Costs and cost-effectiveness of new technologies in cancer. Cancer Policy: Research and Methods, C L Bennett, T J Stinson. Kluwer Academic Publishers, Norwell, Mass 1998; 3
   Google Scholar
• Payers P M, Hand D J. Generalisation from phase III clinical trials: survival, quality of life, and health economics. Lancet 1997; 350: 1025–1027
   PubMed Web of Science ®Google Scholar